Trial Profile
Study on the Effect of 24 Months of Teriparatide Therapy on Bone Microarchitecture and Bone Volume in Postmenopausal Women With Osteoporosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Teriparatide (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacodynamics
- 30 May 2023 Planned End Date changed from 1 Jan 2023 to 1 Jan 2025.
- 30 May 2023 Planned primary completion date changed from 1 Jan 2022 to 1 Jan 2024.
- 28 Sep 2020 Planned End Date changed from 1 Jan 2021 to 1 Jan 2023.